The objective of this study is to determine the efficacy of stanozolol in the treatment of tracheal collapse (TC) in dogs, which is the analogous disease to tracheomalacia (TM) in humans. Twenty-two dogs with endoscopically confirmed and graded TC were enrolled into five groups. Groups 81 (n=5), 82 (n=5) and 83 (n=4) with grade 1, 2 and 3 TC, respectively, received stanozolol orally for 75 days, while groups PI (n=4) and P2 (n=4) with grade 1 and 2 TC, respectively, received placebo. The clinical score was evaluated every 15 days, whereas TC grade was reassessed at the end of the experiment. Clinical improvement was detected from the 30 th day in 82 and 83 group dogs and from the 45 th day in 81 group dogs and continued until the end of the experiment. Also, statistically significant differences were seen between 82 and P2 dogs from the 30 th day, and between 81 and PI dogs from the 60 th day, and continued until the end of the study. Amelioration of the TC grade was seen in 13 of 14 (92.9%) dogs, which received stanozolol. Of the 14 dogs, 57.1% were cured and 35.8% demonstrated a less severe TC grade, while only one dog (7.1%) did not improve at all. Stanozolol seems to be an effective drug in the management of canine TC and it may have potential for use in humans with TM.
Tracheal collapse (TC) in dogs is characterized mainly as a structural and subsequently dynamic defect of tracheal wall, resulting in excessive, usually dorsoventral, flattening of the tracheal lumen. The trachea loses its rigidity and, whenever extraluminal pressure exceeds the intraluminal, it collapses, impeding the air to pass through. The predominant sign of TC is a dry, "goose-honking" cough, while respiratory distress may be rarely seen in advanced cases (1).
Tracheomalacia (TM) in humans represents the analogous disease to TC in dogs (1-2); the crescent type of cartilaginous TM (3), seems to be compatible with the dorsoventral form ofTC. Excessive dynamic airway collapse (EDAC) is currently considered a distinct clinicopathologic entity and it may reflect the dynamic component ofTC (1). Apart from history and physical examination, a thorough diagnostic work-up should be performed in order to establish a definitive diagnosis, in both human and canine disease (4) (5) .
Management of TM is mainly focused on the correction of the primary cause (4) . This is not an option in dogs, because the majority of cases are considered idiopathic (I). Conservative treatment is palliative and not curative ( I, 4) . Several surgical procedures have been used with various, but generally unsatisfactory, results. Indwelling endotracheal stents are considered more promising in both human and canine disease, although longterm evaluation of their complications has not been yet established ( I, 4) .
Recently, the administration of stanozolol, an anabolic androgenic steroid drug, was evaluated in the medical management of TC (6) . Stanozolol might help therapeutically in human and canine disease through its enhancement on protein synthesis (7) , and its action on the increase of chondroitin sulfate content (8) and collagen synthesis (9) . In order to assess the possible benefits from the use of stanozolol in dogs, with various stages of TC, we conducted a double blinded, placebo control clinical trial to compare their clinical and endoscopic status before and after treatment. Furthermore, long-term follow up of these dogs is presented.
MATERIALS AND METHODS

Animals
Twenty-two client-owned dogs presented in the Companion Animal Clinic, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki during a 42-month period from January 2004 to June 2007 were included in the study. In order to include a dog in the study, it had to be affected by the chronic form of TC and its clinical condition to be stable. Furthermore, the owners' compliance to complete diagnostic approach and to the demands of the study protocol was necessary. Dogs were excluded from the study if concurrent to TC cardiovascular (e.g. heart failure, dirofilariosis), systemic (e.g. Cushing's syndrome), and upper (e.g. laryngeal paralysis) or lower respiratory (e.g. bronchopneumonia, chronic bronchitis) diseases, as well as adverse reactions due to stanozolol at any time on the course of its administration, were apparent. The protocol of this study was approved by the Ethics Committee oflocal Veterinary Authorities, and Faculty of Veterinary Medicine. The owners of all the dogs provided their consent for their pets to participate to the study.
Clinical score
A thorough past and present history was obtained. The duration, number and frequency of episodes (mainly cough and/or respiratory distress), namely the character of clinical signs, contributed to a clinical scoring system. Test-retest reliability of answers was evaluated by repeating the questionnaire to the owners of the 22 dogs five days later regarding awareness of the character of clinical signs. Physical examination also contributed to the clinical scoring by tracheal palpation evaluating tracheal ring softening and tracheal sensitivity. All evaluations were performed by two experienced clinicians in nearly standardized environmental conditions. Before the beginning of the present study, the two examiners held a series of sessions on dogs evaluated for similar complaints in order to standardize the assessment of physical examination findings (tracheal ring softening and tracheal sensitivity), and were able to attain high levels of rating reproducibility and interexaminer reliability. Each subcategory of clinical score, namely the character of clinical signs, the tracheal ring softening and the tracheal sensitivity, was graded as I (mild), 2 (moderate), and 3 (severe). In case of non-agreement between the two examiners, the mean value of their grades was used. Subsequently, the clinical score was created by the sum of the individual score of these three parameters.
Laboratory evaluation
Routine haematological and biochemical (total protein, albumin, glucose, ureic acid, creatinine, cholesterol, triglycerides, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bile acids, lipase, potassium, calcium, phosphorus, sodium) analysis, a commercial diagnostic test for Dirofilaria immitis (SnapCanine Heartworm PF, IDEXX, Westbrook, ME, USA), as well as urinalysis and faecal examination (zinc sulfate centrifugation-flotation and Baermann procedure) were performed on presentation, followed by lateral and dorsoventral radiography of the neck and thorax.
Additional diagnostic evaluation
If heart murmurs were detected on physical examination, electrocardiography (ECG) and echocardiography was performed so that heart failure and/or enlarged left atrium that could externally compress the left principal bronchus could be excluded.
Animal preparation
Control of dental disease occurrence was performed 5 days after admission. Dental disease was reported to contribute or to be the cause of cough in small breed dogs with or without TC, respectively (I, 10). A therapeutic trial, consisting of conventional drug administration for TC management was instituted to all the dogs just after diagnostic work-up and dental disease control, where needed, had been completed. Therapeutic trial was deemed necessary because infection and, subsequently, bronchospasm and inflammation could be the cause of the signs of the dogs (10) and it included doxycycline hydrate (5 mg/kg/12 hours per os) and theophylline (10 mg/kg/12 hours per os) for 2 weeks, accompanied by a short-term prednisone administration (0.5 mg/kg/12 hours per os for 5 days). Dogs were re-evaluated 5-7 days after drug discontinuation and clinical score was reassessed. In case of difference between the initial and after therapeutic trial scoring, the latter was taken into account.
Endoscopy
Tracheobronchoscopy was performed after therapeutic trial discontinuation under general anesthesia. TC was confirmed and graded, according to the grading system established by Tangner and Hobson (II). Moreover, larynx and bronchi were assessed and bronchoalveolar lavage fluid (BALF) was obtained, following cell count, cytological examination and culture.
Study protocol
According to tracheoscopy, all 22 dogs suffered from TC; 9 dogs were estimated to have grade I TC, 9 grade 2 TC and 4 grade 3 TC. The dogs were divided into 5 groups. The 9 dogs with grade I TC were arbitrary divided into SI group (n=5), which received stanozolol and PI group (n=4), which received placebo. Similarly, the 9 dogs with grade 2 TC were arbitrary divided into S2 group (n=5), which received stanozolol and P2 group (n=4), which received placebo. Eventually, the 4 dogs with grade 3 TC were allocated in group S3, which received stanozolol. It was not considered ethical to use dogs with grade 3 (severe form) TC in a placebo group.
A laboratory batch of stanozolol tablets was manufactured by the Research and Development Department of VETERIN S.A., Athens, Greece. The manufacturer was GMP accredited and the product was developed in compliance with EU relative legislation. Each tablet contained 2 mg of active ingredient stanozolol and 78 mg of inactive ingredients. The active ingredient was purchased from SIGMA-ALDRICH DEMIE GmBH, Deisenhofen, Germany (code No: S7132, form: powder). The inactive ingredients were the following: talc, sodium lauryl sulfate, magnesium stearate, aerosil 200, pregelatinized starch and qs lactose. The placebo tablets contained 80 mg of the inactive ingredients at exactly the same qualitative composition as that of stanozolol tablets.
Two to three days following endoscopy, stanozolol was initiated in S I, S2 and S3 dogs in the dose of 0.3 mg/ kg, PO, per day, divided, for two months, and then tapered to a I5-day period. Placebo was given in PI and P2 dogs (I tablet, PO, SID, divided) for the same period of time.
The owners were instructed to resubmit the dogs every 15 days. Reevaluation included a detailed history of the last 15 days, physical examination, including clinical scoring, hematology, biochemistry and urinalysis. Stanozolol or placebo was ceased, ifany abnormality was detected.
Seventy-five days after the initiation of therapy, a final evaluation was performed, along with tracheobronchoscopy, during which time the presence and grading of TC was reassessed. During the entire period of the study the examiners and the endoscopist were not aware of the treatment allocation, and the initial grade of TC of any individual dog.
Statistical analysis
In order to summarize the available data, descriptive statistical indices such as percentages (%), measures of central tendency (means, medians), measures of variation (standard deviations, ranges), and correlation coefficience (Cohen's kappa) were calculated.
Median and range were calculated for age, body weight and duration of clinical signs. Data were analyzed into the methodological frame of General Linear Models according to the experimental scheme that consisted of one factor between the animals (group) and one factor within the animals (time) with repeated measures. For the comparisons of means, the Bonferroni test was used. For the statistical comparison of the grade of the TC improvement, the Marginal Homogeneity test was used. In this test, due to the small number of the animals and the nature of the measurement scale (ordinal), the observed significance level (P value) was estimated with the Exact Method. The interexaminer reliability was assessed by means of the Cohen's kappa coefficient. All the statistical analyses were performed using a statistical software (SPSS 15.0; SPSS Inc, Chicago, Ill) enhanced with the module Exact Tests. The significance level of all statistical tests was predetermined at a=0.05.
RESULTS
Epidemiological data
Forty-seven dogs were examined for TC during the study period. Twenty-five dogs were excluded from the study due to several reasons. Fourteen of them were excluded because, concurrently to TC, they also suffered from other diseases. On the contrary, while at least 9 of25 were perfect candidates for this study, their owners were not willing or could not comply with the demands of the protocol, and they abandoned it just at the beginning. Furthermore, in the remaining two dogs increased activity of Table I . Mean ± standard deviation ofclinical score (0-9) every 15 days of22 dogs with tracheal collapse (TC), which received stanozolol (S groups) or placebo (P groups). 
Clinical and laboratory findings
Various degrees of tracheal sensitivity and softening of cartilaginous rings were detected in all dogs, and the characteristic dry honking cough was elicited upon tracheal palpation. Lung sounds were normal, while heart murmur was heard in 3/22 (13.6%) dogs. ECG and echocardiography to assess cardiac function were performed in these 3 dogs. They demonstrated that it was a compensating heart failure with mild dilatation of the left atrium. Various degrees of dental disease were detected in 9/22 (40.9%) dogs and they underwent dental care. Fig. 2 . Endoscopical view ofthe trachea ofa dog with grade 3 tracheal col/apse at its initial presentation (a); note the substantial narrowing ofthe dorsoventral diameter ofthe tracheal lumen (arrow). Endoscopical view ofthe trachea or the same dog after stanozolol administration (b); note that there are not any findings compatible with tracheal col/apse after therapy.
Haematology, biochemistry and urinalysis results were within reference limits for all dogs during the entire period of the study. Similarly, all dogs were negative for heartworm disease and parasitic infestation. Radiographs did not reveal any lung pathology.
Endoscopy findings
Tracheal collapse was confirmed and graded at tracheoscopy. Nine of 22 (40.9%) dogs had grade I TC, 9/22 (40.9%) had grade 2 TC and 4/22 (18.2%) had grade 3 TC. Mild to moderate tracheal mucosal hyperemia was also seen. In all dogs larynx and bronchi were considered functionally and structurally normal. Results of BALF cell count were within reference range and the predominant cells were macrophages followed by limited populations of neutrophils and lymphocytes. Bacterial cultures were negative in all the dogs in the study. The test-retest reliability of owners' answers revealed an exact agreement (100%). The interexaminers' reliability ranged from 0.80 to 0.86.
Clinical scoring evolution
Statistical analysis showed that there was a statistically significant interaction between the factors group and time [F (20, 85)=9.062, P<O.OOI] (Table I; Fig. I) . After drug administration, significant clinical improvement was detected from the 30 th day in the S2 and S3 group dogs and from the 45 th day in S I group dogs, which continued until the end of the experiment. Also, statistically significant difference was observed between S2 and P2 dogs from the 30 th day, while between S I and P I dogs from the 60 th day, which continued until the end of the experiment.
Endoscopical grading evolution
The Marginal Homogeneity test showed that there was a statistically significant, at the significance level of P=0.05, shifting of the dogs which received stanozolol, from the advanced into milder (less severe) stages of TC or healing (Std. MH=3.333, P=O.OOO) (Table II) .
Specifically, 4 dogs of S I, 3 of S2 and I of S3 were negative for TC (57.1%) ( Fig. 2 a and b) . Five (35.8%) dogs moved to a less severe grade (I or 2 TC), while only one dog (7.1%) did not improve endoscopically.
Personal observation andfollow-up
It should be noted that although statistical significance in clinical score was observed from the 30 th day post stanozolol administration in S2 and S3 group dogs, clinical improvement was noticed from the l S" day in all dogs. The end of the follow-up period was set at 2 years post-treatment for all dogs except for dog No. 5 in which the observational period was one year, because he was included late in the course of the study. The dogs were re-evaluated at an annual check-up (detailed history and thorough physical examination) and by telephone communication. The overall impression of stanozolol administration to the owners, and subsequently to us, was enthusiastic.
DISCUSSION
TM is a rare disorder, although its true incidence is unknown, because it is generally considered underdiagnosed (4, (12) (13) . Its severity varies and it is classified as congenital (primary) and acquired (secondary) (14) . Although in TC etiology is generally more obscure, it seems that the two entities meet a similar classification (I, 5, 15) . A combined component of TC etiology has also been proposed in dogs (5, 16) ; the congenital form may be the underlying abnormality and various acquired factors contribute in becoming clinically evident, perpetuating and deteriorating (5) .
Lack of organic matrix, hypocellularity, damaged chondrocytes, loss of normal hyaline cartilage, which is replaced by fibrocartilage or fibrous tissue, and deficiency of chondroitin sulfate, calcium and glucosaminoglycans are the main findings in TC (15) (16) . Similar changes, with various degrees of tracheal cartilage deficiency (17) , have been seen in the cartilaginous form of TM (3, 18) . Stanozolol administration in dogs is indicated for improving appetite, promoting weight gain, and increasing strength and vitality (19) . In general, stanozolol enhances protein synthesis and increases muscle bulk due to its effect on increasing nitrogen retention (7, (20) (21) (22) . This anabolic effect resulted in using stanozolol in the management of protein deficient states, such as debilitating or undernourished patients (23) . Its surprising beneficial effect on wound healing has also been reported (24) . This could be due to the increase of the amount of chondroitin sulfate in wounds caused by the anabolic steroids (8) , the stimulation of procollagen production by stanozolol (25) or its effect on increasing the overall collagen synthesis resulting from the action of TGF-~l (9). This mechanism of action could be attributable to the amelioration of tracheal structure in both human and canine disease, since its pathological mechanism involves decreased concentration of chondroitin sulfate in relation to its collagen content (15) (16) .
Clinical signs of our dogs were compatible with those previously reported (5, (26) (27) . A complete diagnostic work-up is recommended for TC and TM (I, 10, 14) . Tracheobronchoscopy provides the ability to locate and grade the degree of tracheal ring flattening (11) (12) (13) ). The grading system that was established in TC can facilitate in making and evaluating appropriate management decisions and served as a prognostic index(I ).
Management of an individual case with TM or TC could be medical and/or surgical (I, 3). Supportive management is symptomatic and palliative. Various surgical techniques have been described for the management of TC, but unfortunately not all candidates improve by surgical intervention (I). Intraluminal expandable stents are considered promising but, both in humans and dogs, they lack long-term evaluation (14, 27) . However, there is no specific medical treatment available to improve cartilage metabolism or structure (3, 10) . Experimental approaches have been reported with encouraging results (28) (29) .
Significant clinical improvement was noticed in a preliminary report concerning 13 dogs with TC after stanozolol administration (6) . In these dogs, TC was not confirmed endoscopically, meaning that the diagnosis was not definitive. The clinical improvement seen in this study could be due to the steroidal effect of stanozolol (19) . Furthermore, the product that was used (Stargate") was combined with calcium, which could have played a role in the clinical improvement of the dogs with TC. For all these reasons, we designed a clinical study using 22 dogs with TC, which was confirmed and graded endoscopically, in order to evaluate the possible beneficial effect of stanozolol administration not only on the clinical manifestation of TC, but also on the structure of the trachea estimated endoscopically at the end of the study.
Evidence of adverse reactions to stanozolol administration was seen in two dogs, which were excluded from the study. These dogs demonstrated elevation of alkaline phosphatase and alanine aminotransferase activities in serum, but they returned to nonnal two weeks after drug discontinuation. Electrolyte disturbance, hepatotoxicity, behavioral changes, arterial hypertension, cardiomyopathy, lipid metabolism alterations, changes in haemostasis and platelet aggregation, and reproductive abnormalities are considered as the most common adverse effects of stanozolol in humans, and perhaps in dogs, particularly when it is administered in high doses and for long periods of time (19, (20) (21) . From the results of our study, it seems that stanozolol did not cause substantial abnormalities to our dogs at the selected dose and duration of administration.
Stanozolol showed a substantial clinical and endoscopic outcome in dogs with TC. Actually, a long-lasting improvement was seen in approximately 93% of dogs, while 57% of them were completely cured and the rest showed a substantial amelioration of TC. Consequently, it seems that the use of stanozolol contributed to producing a stiffer trachea in dogs with TC. Moreover, stanozolol's anabolic effect could result in increased lean body mass content, which in tum might improve the support of the trachea by the muscles of the neck. Also, its steroidal action could have contributed to limit tracheal mucosal inflammation and thus probably improved clinical status of the dog No.1, which did not show endoscopical improvement.
In conclusion, from the findings of our study it seems that stanozolol may be used for the reconstruction of the trachea and/or substantial clinical improvement of dogs with TC, and it may have potential for use in the conservative treatment in humans with TM.
